Skip to main content
Clinical Trials/DRKS00021218
DRKS00021218
Completed
未知

Effects of serial whole body cryotherapy on disease activity, functional health, cytokines and marker of bone and cartilage metabolism in rheumatoid diseases, e.g, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and primary fibromyalgia, and healthy individuals

Campus Kerckhoff der Justus-Liebig-Universität Gießen0 sites192 target enrollmentApril 8, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
M06.80
Sponsor
Campus Kerckhoff der Justus-Liebig-Universität Gießen
Enrollment
192
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2020
End Date
January 1, 2016
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Campus Kerckhoff der Justus-Liebig-Universität Gießen

Eligibility Criteria

Inclusion Criteria

  • confirmed rheumatoid arthritis according to the ACR/EULAR classification criteria of rheumatoid arthritis of 2010
  • \- confirmed psoriatic arthritis according to the CASPAR criteria
  • \- confirmed axial spondylarthritis / ankylosing arthritis according to the ASAS classification criteria
  • \- confirmed primary fibromyalgia according to the ACR/EULAR criteria of 2010 and the modification of 2011
  • \- Health control subjects after medical examination
  • \- Written consent and approval of the study
  • \- stable medication (antirheumatic as well as analgesic and other basic medication) 4 weeks before starting the study and during the entire study

Exclusion Criteria

  • Contraindications for whole\-body cold therapy treatment (cryoglobulins, cold urticaria, vasculitis, Raynaud's syndrome, unstable arterial hypertension, peripheral arterial circulatory disorders, cold hypersensitivity, disturbed temperature sensation, bladder and kidney diseases, etc.) .
  • No written consent.
  • No comprehension of the study.
  • Lack of German knowledge.
  • Presence of an accompanying secondary pain syndrome in patients with inflammatory rheumatic diseases (RA, PsA, axSpA)

Outcomes

Primary Outcomes

Not specified

Similar Trials